Physician profile
Irene Michelle Dematteo
NPI 1497709497
$9,014.25
in general payments reported to CMS, 2019-2025
21 companies · $1,377 in 2025
The $1,377 reported for 2025 was more than what 92% of Clinical Nurse Specialist providers received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,819 · 2022: $1,987 · 2023: $2,103 · 2024: $1,728 · 2025: $1,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,208.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,224.05 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $903.87 | 2021-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $692.65 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $638.55 | 2021-2025 | Rexulti, Abilify Mycite, Abilify Maintena |
| Axsome Therapeutics, INC. | $514.49 | 2022-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $470.94 | 2022-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $434.50 | 2021-2025 | Caplyta |
| Lundbeck LLC | $393.73 | 2021-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $334.46 | 2022-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $282.70 | 2021-2022 | |
| Tris Pharma INC | $255.91 | 2022-2025 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $228.89 | 2021-2024 | Austedo Xr |
| Corium, LLC | $225.71 | 2022-2025 | Azstarys |
| Neos Therapeutics, Lp | $117.56 | 2021-2024 | Adzenys Xr-Odt |
| Bausch Health US, LLC | $79.64 | 2023-2025 | Aplenzin, Wellbutrin |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $69.02 | 2021-2024 | Spravato |
| Supernus Pharmaceuticals, INC. | $63.34 | 2022-2025 | Qelbree, Qelbree |
| Eisai INC. | $32.80 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.33 | 2024 | Rexulti |
| Almatica Pharma LLC | $15.98 | 2022 | |
| Collegium Pharmaceutical, INC. | $14.13 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irene Dematteo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.